|
AU2009205665B2
(en)
|
2008-01-15 |
2013-12-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for manipulating phagocytosis mediated by CD47
|
|
MX2015007446A
(es)
|
2012-12-12 |
2015-12-07 |
Vasculox Inc |
Anticuerpos terapeuticos para cd47.
|
|
US9221908B2
(en)
|
2012-12-12 |
2015-12-29 |
Vasculox, Inc. |
Therapeutic CD47 antibodies
|
|
ES2914814T3
(es)
|
2012-12-17 |
2022-06-16 |
Pf Argentum Ip Holdings Llc |
Tratamiento de células enfermas CD47+ con fusiones SIRP Alfa-Fc
|
|
US11186640B2
(en)
*
|
2014-07-31 |
2021-11-30 |
The University Of Western Australia |
Method for the identification of immunotherapy-drug combinations using a network approach
|
|
WO2016057980A1
(en)
*
|
2014-10-10 |
2016-04-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods to eliminate cancer stem cells by targeting cd47
|
|
CA2967379A1
(en)
*
|
2014-11-18 |
2016-05-26 |
Janssen Pharmaceutica Nv |
Cd47 antibodies, methods, and uses
|
|
SI3086637T1
(sl)
|
2014-12-05 |
2019-04-30 |
Regeneron Pharmaceuticals, Inc. |
Nehumane živali s humaniziranim označevalcem diferenciacije gena CD47
|
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
TWI778518B
(zh)
*
|
2015-03-04 |
2022-09-21 |
美商索倫多醫療公司 |
結合cd47之抗體治療劑
|
|
CN104804093A
(zh)
*
|
2015-05-27 |
2015-07-29 |
江苏春申堂药业有限公司 |
一种针对cd47的单域抗体
|
|
EP3341015B2
(en)
|
2015-08-26 |
2023-12-27 |
The Board of Trustees of the Leland Stanford Junior University |
Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonist
|
|
EP3347051A4
(en)
*
|
2015-09-10 |
2019-04-24 |
Affigen, Inc. |
SEQUENCING SELECTING TUMOR THEROSTICAS
|
|
BR112018005322A2
(pt)
|
2015-09-18 |
2018-12-11 |
Arch Oncology, Inc. |
anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos
|
|
NZ741324A
(en)
|
2015-09-21 |
2021-09-24 |
Erasmus Univ Medical Center |
Anti-cd47 antibodies and methods of use
|
|
EP3708587B1
(en)
|
2015-11-27 |
2024-05-22 |
Cartherics Pty. Ltd. |
Genetically modified cells and uses thereof
|
|
KR102815803B1
(ko)
|
2015-12-02 |
2025-06-05 |
주식회사 에스티사이언스 |
당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
|
|
EP3747906A1
(en)
|
2016-01-11 |
2020-12-09 |
Forty Seven, Inc. |
Humanized, mouse or chimeric anti-cd47 monoclonal antibodies
|
|
WO2017127707A1
(en)
*
|
2016-01-21 |
2017-07-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Treatment of cancer with combinations of immunoregulatory agents
|
|
AU2017250029C1
(en)
*
|
2016-04-15 |
2022-03-24 |
Pfizer Inc. |
Macrophage stimulation in CD47 blockade therapy
|
|
US12344669B2
(en)
|
2016-06-17 |
2025-07-01 |
Changchun Genescience Pharmaceutical Co., Ltd. |
Anti-CD47 monoclonal antibody and use thereof
|
|
CN106084052B
(zh)
*
|
2016-06-17 |
2019-12-27 |
长春金赛药业股份有限公司 |
抗cd47单克隆抗体及其应用
|
|
CN106117354B
(zh)
*
|
2016-06-24 |
2020-01-14 |
安徽未名细胞治疗有限公司 |
一种全人源抗CD47的全分子IgG抗体及其应用
|
|
JP7241677B2
(ja)
|
2016-07-19 |
2023-03-17 |
テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド |
抗ｃｄ４７併用療法
|
|
BR112019008010A2
(pt)
|
2016-10-20 |
2019-07-09 |
I-Mab |
anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
|
|
EP3529276A4
(en)
*
|
2016-10-21 |
2020-06-17 |
Arch Oncology, Inc. |
CD47 THERAPEUTIC ANTIBODIES
|
|
CA3042581A1
(en)
|
2016-11-03 |
2018-05-11 |
Trillium Therapeutics Inc. |
Enhancement of cd47 blockade therapy by proteasome inhibitors
|
|
WO2018095428A1
(zh)
*
|
2016-11-28 |
2018-05-31 |
江苏恒瑞医药股份有限公司 |
Cd47抗体、其抗原结合片段及其医药用途
|
|
EP3345924A1
(en)
*
|
2017-01-10 |
2018-07-11 |
Universität Duisburg-Essen |
Use of cd47 antibodies
|
|
GB201700621D0
(en)
|
2017-01-13 |
2017-03-01 |
Guest Ryan Dominic |
Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
|
|
EP3574009A4
(en)
|
2017-01-26 |
2020-11-25 |
Zlip Holding Limited |
CD47 ANTIGEN BINDING UNIT AND ITS USES
|
|
BR112019020185A2
(pt)
*
|
2017-03-27 |
2020-06-02 |
Celgene Corporation |
Métodos e composições para redução da imunogenicidade
|
|
CA3057718A1
(en)
*
|
2017-03-28 |
2018-10-04 |
Trillium Therapeutics Inc. |
Cd47 blockade therapy
|
|
EP3652318A1
(en)
|
2017-07-11 |
2020-05-20 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
JP7262440B2
(ja)
*
|
2017-08-02 |
2023-04-21 |
フェインズ セラピューティクス，インコーポレーテッド |
抗ｃｄ４７抗体及びその使用
|
|
EP3668897B1
(en)
*
|
2017-08-18 |
2024-06-05 |
Centessa Pharmaceuticals (UK) Limited |
Binding agents
|
|
CN109422811A
(zh)
*
|
2017-08-29 |
2019-03-05 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
|
SI4177270T1
(sl)
*
|
2017-10-18 |
2024-10-30 |
Forty Seven, Inc. |
Terapija za raka jajčnikov na osnovi sredstva proti cd47
|
|
CN111417653A
(zh)
|
2017-11-01 |
2020-07-14 |
蜂鸟生物科技控股私人有限公司 |
Cd47抗原结合分子
|
|
WO2019090355A1
(en)
*
|
2017-11-06 |
2019-05-09 |
Children's National Medical Center |
Cells expressing antibodies and methods of treatment using the same
|
|
US11771764B2
(en)
|
2017-11-06 |
2023-10-03 |
Pfizer Inc. |
CD47 blockade with radiation therapy
|
|
KR20200091901A
(ko)
|
2017-12-01 |
2020-07-31 |
시애틀 지네틱스, 인크. |
암을 치료하기 위한 cd47 항체 및 이의 용도
|
|
CN110144009B
(zh)
*
|
2018-02-14 |
2020-01-21 |
上海洛启生物医药技术有限公司 |
Cd47单域抗体及其用途
|
|
GB201804860D0
(en)
|
2018-03-27 |
2018-05-09 |
Ultrahuman Two Ltd |
CD47 Binding agents
|
|
CN110305212A
(zh)
*
|
2018-03-27 |
2019-10-08 |
信达生物制药(苏州)有限公司 |
抗cd47抗体及其用途
|
|
US20210155691A1
(en)
*
|
2018-04-16 |
2021-05-27 |
Adaerata, Limited Partnership |
Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers
|
|
CN108484770B
(zh)
*
|
2018-05-16 |
2020-11-13 |
武汉云克隆科技股份有限公司 |
重组大鼠抗小鼠cd4单克隆抗体，制备方法和应用
|
|
CN110538321B
(zh)
*
|
2018-05-29 |
2023-03-10 |
江苏恒瑞医药股份有限公司 |
一种cd47抗体药物组合物及其用途
|
|
CN112566662A
(zh)
|
2018-06-15 |
2021-03-26 |
阿库鲁斯生物科学公司 |
针对cd47的阻断抗体及其使用方法
|
|
CN110615841B
(zh)
*
|
2018-06-20 |
2022-01-04 |
瑞阳(苏州)生物科技有限公司 |
抗人cd47单克隆抗体及其应用
|
|
WO2020014543A2
(en)
|
2018-07-11 |
2020-01-16 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
US20210324075A1
(en)
*
|
2018-08-13 |
2021-10-21 |
Arch Oncology, Inc. |
Therapeutic cd47 antibodies
|
|
EP3844276A2
(en)
|
2018-08-28 |
2021-07-07 |
Actym Therapeutics, Inc. |
Engineered immunostimulatory bacterial strains and uses thereof
|
|
TWI830774B
(zh)
|
2018-08-31 |
2024-02-01 |
大陸商南京聖和藥業股份有限公司 |
抗cd47抗體及其應用
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CN113286613A
(zh)
*
|
2018-10-29 |
2021-08-20 |
Umc乌得勒支控股有限公司 |
IgA介导的通过中性粒细胞的CD47-SIRPα检查点抑制对异常细胞的杀伤
|
|
EP3876977A1
(en)
|
2018-11-06 |
2021-09-15 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
|
EP3892637A1
(en)
*
|
2018-12-03 |
2021-10-13 |
Shanghai Pharmaexplorer Co., Ltd. |
Cd47 antibody, preparation method therefor and uses thereof
|
|
WO2020177733A1
(zh)
|
2019-03-06 |
2020-09-10 |
江苏恒瑞医药股份有限公司 |
双功能融合蛋白及其医药用途
|
|
US11013764B2
(en)
|
2019-04-30 |
2021-05-25 |
Myeloid Therapeutics, Inc. |
Engineered phagocytic receptor compositions and methods of use thereof
|
|
CN114206912B
(zh)
|
2019-06-07 |
2025-02-11 |
Alx肿瘤生物技术公司 |
用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂
|
|
EP3986935A4
(en)
|
2019-06-19 |
2023-08-30 |
Lepu Biopharma Co., Ltd. |
Anti-cd47 antibodies and uses thereof
|
|
WO2020253785A1
(en)
*
|
2019-06-19 |
2020-12-24 |
Lepu Biopharma Co., Ltd. |
Anti-cd47 antibodies and uses thereof
|
|
CN114761041A
(zh)
|
2019-07-16 |
2022-07-15 |
吉利德科学公司 |
Hiv疫苗及其制备和使用方法
|
|
CA3145909A1
(en)
*
|
2019-07-30 |
2021-02-04 |
Yu Xia |
Anti-human p40 protein domain antibody and use thereof
|
|
CN112442123B
(zh)
*
|
2019-09-03 |
2022-08-23 |
中山康方生物医药有限公司 |
抗cd47的单克隆抗体及其用途
|
|
JP7831937B2
(ja)
|
2019-09-03 |
2026-03-17 |
クリエイト・メディシンズ，インコーポレーテッド |
ゲノム組込みのための方法および組成物
|
|
CN114555123B
(zh)
|
2019-10-18 |
2024-04-02 |
四十七公司 |
用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
|
|
JP7520972B2
(ja)
*
|
2019-10-25 |
2024-07-23 |
ウーシー バイオロジクス アイルランド リミテッド |
新規抗ｃｄ４７抗体及びその使用
|
|
KR20220091576A
(ko)
|
2019-10-31 |
2022-06-30 |
포티 세븐, 인코포레이티드 |
혈액암의 항-cd47 및 항-cd20 기반 치료
|
|
US20230042316A1
(en)
*
|
2019-11-20 |
2023-02-09 |
Abvision, Inc. |
Monoclonal antibodies that target human cd47 protein
|
|
GB201918230D0
(en)
|
2019-12-11 |
2020-01-22 |
Prec Therapeutics Ltd |
Antibodies and their uses
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
WO2021123832A1
(en)
|
2019-12-20 |
2021-06-24 |
Instil Bio (Uk) Limited |
Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
|
|
LT4081305T
(lt)
|
2019-12-24 |
2024-11-25 |
Carna Biosciences, Inc. |
Diacilglicerolio kinazę moduliuojantys junginiai
|
|
KR20260017503A
(ko)
|
2020-02-14 |
2026-02-05 |
길리애드 사이언시즈, 인코포레이티드 |
Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
|
|
WO2021190441A1
(zh)
*
|
2020-03-23 |
2021-09-30 |
倍而达药业（苏州）有限公司 |
Cd47/人源化cd47抗体或其抗原结合片段、免疫活性片段及应用
|
|
US12091681B2
(en)
|
2020-03-27 |
2024-09-17 |
Mendus B.V. |
Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
|
|
KR20220163991A
(ko)
*
|
2020-04-02 |
2022-12-12 |
치아타이 티안큉 파마수티컬 그룹 주식회사 |
Cd47에 결합하는 항원-결합 폴리펩타이드 및 이의 용도
|
|
CN111635459B
(zh)
*
|
2020-06-27 |
2021-01-15 |
广东赛尔生物科技有限公司 |
抗cd47抗体及其在治疗癌症中的应用
|
|
CN116133679A
(zh)
|
2020-06-30 |
2023-05-16 |
门德斯有限公司 |
白血病衍生细胞在卵巢癌疫苗中的用途
|
|
EP4240356A1
(en)
|
2020-11-03 |
2023-09-13 |
RDiscovery, LLC |
Therapies for treatment of cancer and phagocytosis-deficiency related diseases
|
|
AU2021373781A1
(en)
*
|
2020-11-04 |
2023-06-22 |
The Trustees Of Dartmouth College |
Vista agonist for treatment/prevention of ischemic and/or reperfusion injury
|
|
CA3197423A1
(en)
|
2020-11-04 |
2022-05-12 |
Daniel Getts |
Engineered chimeric fusion protein compositions and methods of use thereof
|
|
WO2022120286A1
(en)
|
2020-12-06 |
2022-06-09 |
ALX Oncology Inc. |
Multimers for reducing the interference of drugs that bind cd47 in serological assays
|
|
WO2022130016A1
(en)
|
2020-12-18 |
2022-06-23 |
Instil Bio (Uk) Limited |
Tumor infiltrating lymphocytes and anti-cd47 therapeutics
|
|
MX2023009717A
(es)
*
|
2021-02-19 |
2024-01-08 |
Shaperon Inc |
Anticuerpo de dominio individual contra cúmulo de diferenciación 47 (cd47) y uso del mismo.
|
|
KR20230157388A
(ko)
|
2021-03-12 |
2023-11-16 |
멘두스 비.브이. |
백신접종의 방법 및 cd47 차단의 용도
|
|
CN112979764B
(zh)
*
|
2021-03-26 |
2022-08-02 |
复旦大学附属中山医院 |
特异结合人cd47分子的多肽及其用途
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
AU2022272235A1
(en)
|
2021-05-11 |
2023-12-21 |
Create Medicines, Inc. |
Methods and compositions for genomic integration
|
|
WO2022271659A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CA3222277A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
WO2022271677A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
KR20240005901A
(ko)
|
2021-06-23 |
2024-01-12 |
길리애드 사이언시즈, 인코포레이티드 |
디아실글리세롤 키나제 조절 화합물
|
|
US20230183216A1
(en)
|
2021-10-28 |
2023-06-15 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
EP4422756A1
(en)
|
2021-10-29 |
2024-09-04 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
EP4452415B1
(en)
|
2021-12-22 |
2026-02-25 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN118488946A
(zh)
|
2021-12-22 |
2024-08-13 |
吉利德科学公司 |
Ikaros锌指家族降解剂及其用途
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
WO2023159220A1
(en)
*
|
2022-02-18 |
2023-08-24 |
Kenjockety Biotechnology, Inc. |
Anti-cd47 antibodies
|
|
CA3253296A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
|
|
AU2023240346A1
(en)
|
2022-03-24 |
2024-09-19 |
Gilead Sciences, Inc. |
Combination therapy for treating trop-2 expressing cancers
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
WO2023205719A1
(en)
|
2022-04-21 |
2023-10-26 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20240116928A1
(en)
|
2022-07-01 |
2024-04-11 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
CN119677546A
(zh)
|
2022-07-12 |
2025-03-21 |
吉利德科学公司 |
Hiv免疫原性多肽和疫苗及其用途
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
EP4638436A1
(en)
|
2022-12-22 |
2025-10-29 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
CN120882725A
(zh)
|
2023-04-11 |
2025-10-31 |
吉利德科学公司 |
Kras调节化合物
|
|
WO2024220917A1
(en)
|
2023-04-21 |
2024-10-24 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
AU2024297978A1
(en)
|
2023-07-26 |
2026-02-05 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
AU2024337913A1
(en)
|
2023-09-08 |
2026-03-26 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250154172A1
(en)
|
2023-11-03 |
2025-05-15 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
CN120648654A
(zh)
*
|
2024-03-13 |
2025-09-16 |
深圳太力生物技术有限责任公司 |
重组细胞的制备方法、重组细胞及其应用
|
|
US20250376484A1
(en)
|
2024-05-21 |
2025-12-11 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|